Plumbline Life Sciences플럼라인생명과학
222670 · KONEX · ₩222670 · 플럼라인생명과학
- Market cap
- ₩19B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−25.1% from the high
₩4,200Today: ₩4,635 – ₩4,635₩6,190
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD−9.1%
- 1Y−23.3%
- Volume today
- —
- Traded today
- —
- Listed shares
- 4,032,932
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Plumbline Life Sciences stock overview
Plumbline Life Sciences (플럼라인생명과학, KRX: 222670) is listed on KONEX, in the Biotech & Pharma sector. Plumeline Life Sciences is a Korean biotech venture that researches, develops and produces animal DNA medicines using its proprietary DNA drug platform and CELLECTRA electroporation delivery device, with the goal of bringing next-generation veterinary innovative drugs to global markets. Its shares closed at ₩4,635 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩19B.
Key facts
- Market cap
- ₩19B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- Plumeline Life Sciences is a Korean biotech venture that researches, develops and produces animal DNA medicines using its proprietary DNA drug platform and CELLECTRA electroporation delivery device, with the goal of bringing next-generation veterinary innovative drugs to global markets.
Quick answers about Plumbline Life Sciences
- What does Plumbline Life Sciences do?
- Plumeline Life Sciences is a Korean biotech venture that researches, develops and produces animal DNA medicines using its proprietary DNA drug platform and CELLECTRA electroporation delivery device, with the goal of bringing next-generation veterinary innovative drugs to global markets. 0, a DNA immunomodulator for sows that is approved in Australia and New Zealand and in Korea for import. The company also pursues licensing and open-innovation partnerships, and it was founded in 2014 after acquiring assets of VGX Animal Health in the United States.
- What is the market cap of Plumbline Life Sciences?
- The market capitalisation of Plumbline Life Sciences was ₩19B at the close on Oct 27, 2026.
- Who are the largest shareholders of Plumbline Life Sciences?
- According to the latest official filings, the largest reported holders are Shin Yong-ju (7.10%, as of Nov 18, 2025).
- When is the next earnings report from Plumbline Life Sciences?
- Korean companies rarely announce results dates in advance. Based on when Plumbline Life Sciences filed the same report in past years, its next annual results is expected between Mar 19, 2027 and Mar 20, 2027.
Company profile
Plumeline Life Sciences is a Korean biotech venture that researches, develops and produces animal DNA medicines using its proprietary DNA drug platform and CELLECTRA electroporation delivery device, with the goal of bringing next-generation veterinary innovative drugs to global markets. Its pipeline includes PLS-D1000, a DNA healthy-aging treatment for senior dogs approved in Korea in October 2024, PLS-D5000, a DNA immunotherapy for dogs with cancer, PLS-ASF, an African swine fever DNA vaccine, and LifeTide SW5.0, a DNA immunomodulator for sows that is approved in Australia and New Zealand and in Korea for import. The company also pursues licensing and open-innovation partnerships, and it was founded in 2014 after acquiring assets of VGX Animal Health in the United States.
Written by AI from the company's latest annual report.
- Korean name
- 플럼라인생명과학
- Sector
- Biotech & Pharma
- CEO
- 김앤토니경태
- Founded
- Jan 2014
- Listed
- Jul 2015
- Listed shares
- 4,032,932
- Fiscal year ends
- Month 12
- Website
- www.plsdna.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Major sales or supply contractApr 3, 2026
- Annual general meeting resultsMar 31, 2026
- DelistingMar 24, 2026
- Trading haltMar 24, 2026
- Added attachment: Annual report (Dec 2025)Mar 23, 2026
Titles in Korean until English translations are added.
Also known as: Plumbline Life Sciences / 플럼라인생명과학 / 222670 / KRX:222670
Source: KRX statistical information